Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer

M. Marzola, G. Parma, C. Bonazzi, N. Colombo, A. Maneo, M. R. Pittelli, C. Mangioni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To evaluate the anti-tumour activity and toxicity of ifosfamide (5 g/m 2 continuous infusion) and mitoxantrone (10 mg/m 2) given in combination every 3 weeks in patients with ovarian cancer resistant to at least two previous regimens which included platinum. Patients and methods: Additional eligibility criteria were an ECOG performance status ≤2 and measurable disease. Of 47 patients entered in the study, 8 were defined as platinum-resistant and 39 as potentially sensitive according to Markman's criteria. Thirty-five patients had also received paclitaxel as last treatment before entering this study. Tumour response was evaluated every three cycles. Results: One complete and 11 partial responses were reported, for an overall response rate of 25% (95% CI: 14%-40%). Three of the partial responders were resistant to platinum. None of the 7 partial responders pretreated with taxol had responded to it. The overall median survival was 11 months. Neutropenia G4 was reported in 18 patients (42%) with hospitalisation because of febrile neutropenia in 3 of them. Conclusions: In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity. Objective responses were reported also in patients failing paclitaxel, suggesting a lack of cross resistance.

Original languageEnglish
Pages (from-to)419-421
Number of pages3
JournalAnnals of Oncology
Volume7
Issue number4
Publication statusPublished - Apr 1996

Fingerprint

Salvage Therapy
Mitoxantrone
Ifosfamide
Ovarian Neoplasms
Paclitaxel
Platinum
Febrile Neutropenia
Neutropenia
Neoplasms
Hospitalization
Survival
Therapeutics

Keywords

  • Ifosfamide
  • Mitoxantrone
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marzola, M., Parma, G., Bonazzi, C., Colombo, N., Maneo, A., Pittelli, M. R., & Mangioni, C. (1996). Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Annals of Oncology, 7(4), 419-421.

Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. / Marzola, M.; Parma, G.; Bonazzi, C.; Colombo, N.; Maneo, A.; Pittelli, M. R.; Mangioni, C.

In: Annals of Oncology, Vol. 7, No. 4, 04.1996, p. 419-421.

Research output: Contribution to journalArticle

Marzola, M, Parma, G, Bonazzi, C, Colombo, N, Maneo, A, Pittelli, MR & Mangioni, C 1996, 'Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer', Annals of Oncology, vol. 7, no. 4, pp. 419-421.
Marzola M, Parma G, Bonazzi C, Colombo N, Maneo A, Pittelli MR et al. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Annals of Oncology. 1996 Apr;7(4):419-421.
Marzola, M. ; Parma, G. ; Bonazzi, C. ; Colombo, N. ; Maneo, A. ; Pittelli, M. R. ; Mangioni, C. / Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. In: Annals of Oncology. 1996 ; Vol. 7, No. 4. pp. 419-421.
@article{4e22c4f962a64dfea44b0cff93037953,
title = "Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer",
abstract = "Objective: To evaluate the anti-tumour activity and toxicity of ifosfamide (5 g/m 2 continuous infusion) and mitoxantrone (10 mg/m 2) given in combination every 3 weeks in patients with ovarian cancer resistant to at least two previous regimens which included platinum. Patients and methods: Additional eligibility criteria were an ECOG performance status ≤2 and measurable disease. Of 47 patients entered in the study, 8 were defined as platinum-resistant and 39 as potentially sensitive according to Markman's criteria. Thirty-five patients had also received paclitaxel as last treatment before entering this study. Tumour response was evaluated every three cycles. Results: One complete and 11 partial responses were reported, for an overall response rate of 25{\%} (95{\%} CI: 14{\%}-40{\%}). Three of the partial responders were resistant to platinum. None of the 7 partial responders pretreated with taxol had responded to it. The overall median survival was 11 months. Neutropenia G4 was reported in 18 patients (42{\%}) with hospitalisation because of febrile neutropenia in 3 of them. Conclusions: In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity. Objective responses were reported also in patients failing paclitaxel, suggesting a lack of cross resistance.",
keywords = "Ifosfamide, Mitoxantrone, Ovarian cancer",
author = "M. Marzola and G. Parma and C. Bonazzi and N. Colombo and A. Maneo and Pittelli, {M. R.} and C. Mangioni",
year = "1996",
month = "4",
language = "English",
volume = "7",
pages = "419--421",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer

AU - Marzola, M.

AU - Parma, G.

AU - Bonazzi, C.

AU - Colombo, N.

AU - Maneo, A.

AU - Pittelli, M. R.

AU - Mangioni, C.

PY - 1996/4

Y1 - 1996/4

N2 - Objective: To evaluate the anti-tumour activity and toxicity of ifosfamide (5 g/m 2 continuous infusion) and mitoxantrone (10 mg/m 2) given in combination every 3 weeks in patients with ovarian cancer resistant to at least two previous regimens which included platinum. Patients and methods: Additional eligibility criteria were an ECOG performance status ≤2 and measurable disease. Of 47 patients entered in the study, 8 were defined as platinum-resistant and 39 as potentially sensitive according to Markman's criteria. Thirty-five patients had also received paclitaxel as last treatment before entering this study. Tumour response was evaluated every three cycles. Results: One complete and 11 partial responses were reported, for an overall response rate of 25% (95% CI: 14%-40%). Three of the partial responders were resistant to platinum. None of the 7 partial responders pretreated with taxol had responded to it. The overall median survival was 11 months. Neutropenia G4 was reported in 18 patients (42%) with hospitalisation because of febrile neutropenia in 3 of them. Conclusions: In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity. Objective responses were reported also in patients failing paclitaxel, suggesting a lack of cross resistance.

AB - Objective: To evaluate the anti-tumour activity and toxicity of ifosfamide (5 g/m 2 continuous infusion) and mitoxantrone (10 mg/m 2) given in combination every 3 weeks in patients with ovarian cancer resistant to at least two previous regimens which included platinum. Patients and methods: Additional eligibility criteria were an ECOG performance status ≤2 and measurable disease. Of 47 patients entered in the study, 8 were defined as platinum-resistant and 39 as potentially sensitive according to Markman's criteria. Thirty-five patients had also received paclitaxel as last treatment before entering this study. Tumour response was evaluated every three cycles. Results: One complete and 11 partial responses were reported, for an overall response rate of 25% (95% CI: 14%-40%). Three of the partial responders were resistant to platinum. None of the 7 partial responders pretreated with taxol had responded to it. The overall median survival was 11 months. Neutropenia G4 was reported in 18 patients (42%) with hospitalisation because of febrile neutropenia in 3 of them. Conclusions: In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity. Objective responses were reported also in patients failing paclitaxel, suggesting a lack of cross resistance.

KW - Ifosfamide

KW - Mitoxantrone

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0030017940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030017940&partnerID=8YFLogxK

M3 - Article

C2 - 8805937

AN - SCOPUS:0030017940

VL - 7

SP - 419

EP - 421

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -